ASA and Pacira BioSciences strengthen strategic collaboration focused on education, quality improvement and patient outcomes. Newswise - CHICAGO - The American Society of Anesthesiologists (ASA) today announced the continued expansion of its collaboration with Pacira BioSciences, Inc. through ASA's Corporate Supporter Program. Building on three years of engagement, ASA and Pacira are working to advance shared priorities in physician education, advocacy, quality improvement and evidence-based non-opioid approaches to pain management that support improved patient outcomes. "Our collaboration with Pacira has grown into a shared effort to improve accelerating patient care," said ASA President Patrick Giam, M.D., FASA. "Through ongoing dialogue and shared initiatives, we are advancing education for anesthesiologists, strengthening advocacy efforts and supporting quality improvement across the specialty. Together, we are working to ensure anesthesiologists have the knowledge and resources to deliver the highest-quality care for patients." Earlier this spring, ASA and Pacira leadership met to discuss shared priorities and identify opportunities for collaboration. Those discussions led to the formation of joint workstreams focused on supporting the NOPAIN for Veterans Act and the reauthorization of the NOPAIN Act, both of which aim to ensure increased patient and provider access to qualifying non-opioid pain management options. Discussions also focused on opportunities to leverage quality improvement initiatives and data registries to enhance patient outcomes. Through the Corporate Supporter Program, ASA and Pacira have established a strategic relationship focused on advancing the specialty of anesthesiology and improving patient care. Pacira is on ASA's Center for Perioperative Medicine Corporate Advisory Council, a forum for dialogue among industry and physician leaders focused on advancing perioperative care, patient safety, quality improvement, and innovation. Pacira will also host an interactive Satellite Symposium at ANESTHESIOLOGY(R) 2026 on the TEAM model, with related content planned for future webinars and microlearning videos. "Pacira is proud to continue our collaboration with ASA to advance education, advocacy and quality improvement initiatives that help anesthesiologists deliver evidence-based, patient-centered care," said Frank D. Lee, chief executive officer of Pacira BioSciences. "Together, we are focused on expanding awareness of non-opioid options for pain management and supporting approaches that can improve patient outcomes throughout the post-surgical recovery journey." Established in 2010, ASA's Corporate Supporter Program is limited to 10 organizations. The program recognizes leading companies that demonstrate a sustained commitment to advancing the specialty of anesthesiology through support of education, innovation, and initiatives that benefit anesthesiologists and the Anesthesia Care Team. About Pacira BioSciences Pacira BioSciences, Inc. is a biotechnology company focused on advancing non-opioid approaches to pain management. The company works with clinicians and health care organizations to support education and evidence-based approaches that help improve patient care. For more information, visit pacira.com. About the American Society of Anesthesiologists Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 60,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings.

Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, its investigational gene therapy for moderate-to-severe knee osteoarthritis. The treatment was well tolerated and showed exploratory improvements in pain, stiffness, and function. The company has advanced Phase 2 enrollment and confirmed successful scale-up to a commercial-ready manufacturing process. PCRX-201 is the first gene therapy for knee osteoarthritis to combine sustained clinical results with RMAT and ATMP regulatory designations. Analysts project the company's revenue will reach $908.9 million by 2028, requiring 8.8% yearly growth. The most pessimistic forecasts estimate roughly $865 million revenue and $97 million earnings, with about 6% annual revenue growth. The core EXPAREL franchise currently drives most of Pacira's financial results.

Pacira: Q2 earnings snapshot. August 4, 2026, 4:39 PM BRISBANE, Calif. (AP) - BRISBANE, Calif. (AP) - Pacira Pharmaceuticals Inc. (PCRX) on Tuesday reported earnings of $4.7 million in its second quarter. On a per-share basis, the Brisbane, California-based company said it had profit of 12 cents. Earnings, adjusted for one-time gains and costs, came to 73 cents per share. The specialty drugmaker posted revenue of $192.4 million in the period. Pacira expects full-year revenue in the range of $735 million to $760 million. Keep Watching 1 dead, 7 injured after two-vehicle crash in Germantown This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PCRX at https://www.zacks.com/ap/PCRX